Efficacy of low dose nivolumab in recurrent / metastatic cervical cancer

被引：1
|
作者：
Devabhaktuni, S. [1 ]
Singh, A. [1 ]
Georgy, J. T. [1 ]
Antonisamy, J. [1 ]
Thumaty, D. B. [1 ]
John, A. O. [1 ]
机构：
[1] CMC Christian Med Coll Hosp, Med Oncol Dept, Vellore, Tamil Nadu, India
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.408
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
286MO
引用
收藏
页码：S1585 / S1585
页数：1
相关论文
共 50 条
  • [21] Retreatment with nivolumab for patients with recurrent and/or metastatic head and neck cancer
    Wakasugi, Tetsuro
    Takeuchi, Shoko
    Ohkubo, Jun-ichi
    Suzuki, Hideaki
    ACTA OTO-LARYNGOLOGICA, 2022, 142 (02) : 206 - 212
  • [22] Efficacy and safety of nivolumab (Nivo) plus ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358
    Naumann, R. W.
    Oaknin, A.
    Meyer, T.
    Lopez-Picazo, J. M.
    Lao, C.
    Bang, Y-J.
    Boni, V.
    Sharfman, W. H.
    Park, J. C.
    Devriese, L. A.
    Harano, K.
    Chung, C. H.
    Topalian, S. L.
    Zaki, K.
    Chen, T.
    Gu, J.
    Li, B.
    Barrows, A.
    Horvath, A.
    Moore, K. N.
    ANNALS OF ONCOLOGY, 2019, 30 : 898 - +
  • [23] Low dose nivolumab in metastatic mucosal melanoma: a case report
    Meraz-Brenez, Andres
    Navarrete-Reyes, Ana P.
    Ignacio-Alvarez, Eleazar
    Ramirez-Anguiano, Georgina J.
    Verduzco-Aguirre, Haydee C.
    GACETA MEXICANA DE ONCOLOGIA, 2023, 22 (03): : 140 - 145
  • [24] Efficacy and safety of EGFR inhibitor gefitinib in recurrent or metastatic cervical cancer: a preliminary report
    Krishna, Abhishek
    Sathya, M.
    Mukesh, S.
    Athiyamaan, M. S.
    Banerjee, Sourjya
    Sunny, Johan
    Srinivas, Challapalli
    Lobo, Dilson
    Makkapatti, Bharat Sai
    Jawahar, Vaishak
    MEDICAL ONCOLOGY, 2023, 40 (07)
  • [25] The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study
    Yu, Jiangtao
    Xu, Ziwen
    Li, Anyang
    Zhang, Jindi
    Wang, Yi
    Zhao, Hongqin
    Zhu, Haiyan
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 3419 - 3424
  • [26] Efficacy and safety of EGFR inhibitor gefitinib in recurrent or metastatic cervical cancer: a preliminary report
    Abhishek Krishna
    M. Sathya
    S. Mukesh
    M. S. Athiyamaan
    Sourjya Banerjee
    Johan Sunny
    Challapalli Srinivas
    Dilson Lobo
    Bharat Sai Makkapatti
    Vaishak Jawahar
    Medical Oncology, 40
  • [27] Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
    Colombo, N.
    Dubot, C.
    Lorusso, D.
    Caceres, M., V
    Hasegawa, K.
    Shapira-Frommer, R.
    Tewari, K. S.
    Salman, P.
    Usta, E. Hoyos
    Yanez, E.
    Gumus, M.
    de Mendoza, M. Olivera Hurtado
    Samouelian, V
    Castonguay, V
    Arkhipov, A.
    Toker, S.
    Li, K.
    Keefe, S. M.
    Monk, B. J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (20): : 1856 - 1867
  • [28] Immunotherapy for Recurrent and Metastatic Cervical Cancer: A Review
    Wu, Yuke
    He, Xiang
    CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, 2024, 51 (07):
  • [29] Current management of recurrent/metastatic cervical cancer
    Tewari, Krishnansu Sujata
    ANNALS OF ONCOLOGY, 2023, 34 : S1358 - S1358
  • [30] The Role of Immunotherapy in Recurrent or Metastatic Cervical Cancer
    Randall, Leslie M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (07) : 435 - 437
12345